1 / 13

Africa ’ s Public Health Challenges

Making Africa a competitor in the Global Pharmaceutical Industry: Implementation of the Pharmaceutical Manufacturing Plan for Africa. AWA Consultative Experts ’ Committee Meeting of Commission of the African Union, Nouakchott, Mauritania 27-28 May 2014 Dr Paul Lartey, FAPMA Chairperson.

glynn
Télécharger la présentation

Africa ’ s Public Health Challenges

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Making Africa a competitor in the Global Pharmaceutical Industry: Implementation of the Pharmaceutical Manufacturing Plan for Africa AWA Consultative Experts’ Committee Meeting of Commission of the African Union, Nouakchott, Mauritania27-28 May 2014 Dr Paul Lartey, FAPMA Chairperson

  2. Africa’s Public Health Challenges • Heavy burden of HIV/AIDS: top cause of morbidity and mortality in Sub-Sahara Africa; • Upsurge in tuberculosis and other opportunistic infections; • Future disease burden • 60 million people with hypertension by 2020 • 1 million cases of cancer annually • 18.6 million people with diabetes by 2020 • Other CVS, chronic respiratory diseases (COPD / asthma) and neuro-psychiatric conditions • NCD’s will have surpassed infectious diseases as the leading cause of death in Africa by 2030. Source: WHO, WHO AFRO, Frost & Sullivan analysis

  3. Pharmaceutical Manufacturing Plan for Africa - PMPA • African Heads of State recognized the need for a sustainable strategy with treatment as central point • This in turn implies the need for readily available efficacious, high quality and affordable medicines • AU Heads of State meeting of July 2012 accepted the PMPA Business Plan

  4. PMPA Vision To develop a competitive and enduring integrated pharmaceutical manufacturing industry in Africa, able to respond to the continent’s need for a secure and reliable supply of quality, affordable, accessible, safe and efficacious medicines.

  5. Key Issues and Package of Solutions

  6. Active in Entire Pharma Value Chain

  7. Research into Neglected Diseases

  8. PMPA: Partnering for Implementation • World health Organization (WHO) and United States Pharmacopeia convention’s Promoting the Quality of Medicines program. • These organizations are assisting with capacity development in regulation and GMP. • The United Nations Industrial Development Organization (UNIDO) is playing a much-needed coordinating role in the implementation of the PMPA BP, through a consortium comprising representation from all stakeholders. • Other partners are the United Nations Development Program (UNDP), the Joint United nations Program on HIV/AIDS (UNAIDS), United Nations Population Fund (UNFPA) and the African Development Bank.

  9. Federation of African Pharmaceutical Manufacturers Associations • Member Organizations: • Federation of East African Pharmaceutical Manufacturers • Southern African Generic Medicines Association • West African Pharmaceutical Manufacturers Association

  10. FAPMA Membership FAPMA 231 manufacturers

  11. FAPMA Objectives • To promote excellence in the pharmaceutical industry • Promote access to safe, quality, efficacious medicines in Africa • To strengthen local production of medicines so as to meet needs of the continent • Facilitate economic growth through development of a sustainable, self-sufficient and viable pharmaceutical industry in Africa industry

  12. Factors impacting on industry capacity • Unfair competition from fake and substandard imported medicines • Price competition against imported highly subsidized medicines from Asia • Inadequate patronage by African governments

  13. Way Forward • Aligned visions of PMPA BP and FAPMA demonstrates commitment • Mix of capacity development measures, incentives and patronage, strengthen of 236 Africa-based pharmaceutical manufacturers Global competitiveness is imminently possible

More Related